开发一种具有通用药物加载能力的药物传递平台，以满足癌症治疗的各种需求，是一项具有挑战性但有趣的任务。在此，通过微相分离和脱溶过程，开发了一种基于明胶/丝素组合微粒（GSC）的自组装药物传递系统。由于其预组装的微相阶段，该GSC系统适用于各种类型的药物。脱溶过程可迅速固定药物于GSC内，并致密GSC结构，从而实现高效药物加载并为已载药物提供全面的保护。事实上，这种全新的非孔洞依赖型药物传递系统的尺寸可轻松调整为100 nm至20 μm，以适应不同环境。我们选择直径为3 μm的GSC作为通用吸入药物传递平台，其显示出优异的经粘膜渗透和肺滞留能力。此外，GSC的MMP-9敏感降解特性增强了药物的靶向效率并减少了副作用。更重要的是，GSC可以自增强内源免疫调控，将癌症微环境逆转为抗肿瘤的生态环境，显著提高药物的治疗效果。我们对GSC通用药物平台的研究为肺癌的下一代药物传递系统的开发提供了新的方向。本文受版权保护，保留所有权利。

Developing a drug delivery platform that possesses universal drug loading capacity to meet various requirements of cancer treatment is a challenging yet interesting task. Herein, a self-assembled gelatin/silk fibroin composite particle (GSC) based drug delivery system is developed via microphase separation followed by desolvation process. Thanks to its pre-assembled microphase stage, this GSC system is suitable for varying types of drugs. The desolvation process fix drugs inside GSC rapidly and densify the GSC structure, thereby achieving efficient drug loading and providing comprehensive protection for loaded drugs. Actually, the size of this brand-new non-pore dependent drug delivery system can be easily adjusted from 100 nm to 20 μm to fit different scenarios. We select GSC with 3 μm diameter as the universal inhaled drug delivery platform, which shows an excellent transmucosal penetration and lung retention ability. Additionally, the MMP-9 sensitive degradation property of GSC enhances the targeted efficiency of drugs and reduces side effects. Intestinally, GSC can self-amplify the regulation of innate immunity to reverse the cancerous microenvironment into an anti-tumor niche, significantly improving the therapeutic effect of drugs. Our study of GSC universal drug platform provides a new direction to develop the next-generation of drug delivery system for lung cancer. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.